Table 2.
Descriptive characteristics and outcomes for all LR-PAC patients that underwent MRgSBRT
| Total (N = 15) | |
|---|---|
| Median age (years) | 69.2 (50.4–82.0) |
| Female | 8 (53%) |
| Histology at initial biopsy | |
| Ductal adenocarcinoma | 15 (100%) |
| Pathologic staging at initial resection | |
| IA | 1 (6.7%) |
| IB | 5 (33.3%) |
| IIA | 0 (0%) |
| IIB | 3 (20%) |
| III | 6 (40%) |
| IV | 0 (0%) |
| Median KPS at MRgSBRT | 80 (60–100) |
| Median BMI at MRgSBRT | 25.9 (17.8–32.0) |
| Neoadjuvant chemoRT | 1 (6.7%) |
| Adjuvant chemoRT | 1 (6.7%) |
| Adjuvant chemotherapy without RT | 12 (80%) |
| FOLFIRINOX | 5 (33.3%) |
| Gemcitabine and Capecitabine | 3 (20%) |
| Gemcitabine and Nab-Paclitaxel | 1 (6.7%) |
| Gemcitabine and Cisplatin | 1 (6.7%) |
| Gemcitabine alone | 1 (6.7%) |
| Capecitabine | 1 (6.7%) |
| Median time resection to recurrence (mos) | 16.2 (2.6–48.6) |
| Median time from resection to MRgSBRT (mos) | 18.8 (3.5–52.8) |
| Median follow up from MRgSBRT (mos) | 10.6 (2.8–24.8) |
| Median overall survival (mos) | 33.9 (12.4–59.7) |
| Median survival time from recurrence (mos) | 14.1 (3.2–25.6) |
| Median time to distant failure from MRgSBRT | 2.9 (0.3–6.7) |
| Grade 1–2 GI acute toxicity | 7 (46.7%) |
| Grade 1–2 GI late toxicity | 4 (30.8%) |